Prime Minister Manuel Valls, who vows to slash spending and lower taxes on business, could either sink or replace French President Hollande
Fiat Chrysler's police vehicle is a muscle car with cool features and the rear-wheel drive that many cops prefer
Its purchases alarm some right-wing conspiracy theorists, but in fact its ammo buying has been declining for years
Apple's iPhone sales last quarter exceed estimates, while iPad sales disappoint
Its revenue keeps rising, and it keeps adding more customers
Apple's new campus, designed by Stephen Behling and Sir Norman Foster, is raising some eyebrows
Amazon will be the first Internet-TV provider to stream HBO shows—if not new ones—by offering them on Instant Video and its Fire TV device
Expatriate professionals prepare for change when they set off to work abroad, but the real shock awaits their return to the corporation
Startup Casper bets it can sell foam-only bedding via a Web-only, direct-to-consumer business model
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.